Chat
Des-gamma-carboxy Prothrombin
Copy Utility
Ordering Recommendation
Surveillance and monitoring of hepatocellular carcinoma.
Mnemonic
Methodology
Quantitative Liquid Chromatography/Immunoassay
Performed
Mon,Thu
Reported
1-5 days
New York DOH Approval Status
Specimen Required
Plain red or serum separator tube.
Allow specimen to clot completely at room temperature. Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Refrigerated.
Plasma.
After separation from cells: Ambient: 8 hours; Refrigerated: 1 week; Frozen: 3 weeks (avoid repeated freeze/thaw cycles)
Reference Interval
Effective August 20, 2012
0.0 - 7.4 ng/mL
Interpretive Data
The µTASWako method is used. Results obtained with different assay methods or kits cannot be used interchangeably. The des-gamma-carboxy prothrombin (DCP) assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases. Elevated DCP values have been shown to be associated with an increased risk for developing hepatocellular carcinoma. Patients with elevated serum DCP should be more intensely evaluated for evidence of hepatocellular carcinoma. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.
Medication containing vitamin K preparations may cause a negative bias of the DCP values.
Medication containing vitamin K antagonist or antibiotic may cause a positive bias of the DCP values.
FDA
Note
Hotline History
CPT Codes
83951
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0081327 | Des-gamma-carboxy Prothrombin | 34444-0 |
Aliases
- DCP
- PIVKA-II
Feedback
